Lilly Reinforces its Commitment to Rheumatology through Data Showcased at the ACR/ARP Annual Meeting
- Friday, November 8, 2019, 7:10
- PR Newswire
- Add a comment
INDIANAPOLIS, Nov. 8, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that it will present new data from Taltz® (ixekizumab) and Olumiant® (baricitinib) at the American College of Rheumatology (ACR)/Association of Rheumatology Professionals (ARP) annual meeting…
About the Author
admin has written 21721 stories on this site.